Pinealon vs Cortexin
Both are Russian-origin peptide compounds with cognitive-relevance research applications, but with distinctly different compound architectures and evidence-base positioning. Pinealon is a defined tripeptide within the Khavinson short-peptide bioregulator research programme; Cortexin is a bovine-cortex-derived multi-component polypeptide preparation with substantial Russian licensed clinical use particularly in paediatric neurological indications.
At a glance
| Pinealon | Cortexin | |
|---|---|---|
| Structural class | Tripeptide (Glu-Asp-Arg) | Bovine-cortex multi-component polypeptide preparation |
| Manufacturer / origin programme | Khavinson group (St Petersburg) | Geropharm (Russia) |
| Primary route | Oral bioregulator or parenteral | Intramuscular injection |
| Russian registration | Not assessed | Registered (Vidal.ru), dispensed by prescription |
| UK status | No emc entry found (checked 17 October 2026) | No emc entry found (checked 17 October 2026) |
| Clinical evidence base | Preclinical primary | Substantial Russian clinical evidence base, paediatric neurology emphasis |
| Evidence tier | C | B |
| Signature indication research angle | Cognitive-ageing preclinical research | Post-stroke, TBI, paediatric neurological indications |
Compound architecture and manufacturing
Defined bioregulator versus tissue-extract preparation
Pinealon is a defined tripeptide (Glu-Asp-Arg) manufactured by controlled peptide synthesis within the Khavinson short-peptide bioregulator programme. The manufacturing is straightforward — a defined chemical synthesis producing a single molecule with characterised purity.
Cortexin is a multi-component polypeptide preparation manufactured by Geropharm (Russia) through controlled proteolytic digestion of purified bovine cortex tissue. The preparation is not a single molecule but a defined-composition biological product; the manufacturing process controls batch-to-batch composition consistency.
This architectural difference means Pinealon's clinical adoption profile is more limited than Cortexin's — the defined tripeptide has not achieved the paediatric-neurology licensed indication traction that Cortexin has in the Russian/CIS clinical framework.
Clinical positioning
Preclinical research tool versus licensed paediatric-neurology adjunct
Pinealon's clinical positioning is primarily as a research-tool for probing the Khavinson short-peptide-bioregulator hypothesis in cognitive-decline research applications. Evidence-base is preclinical primary, with human cognitive-endpoint clinical trial coverage limited relative to the preclinical body.
Cortexin's clinical positioning is that of a mature licensed pharmaceutical within the Russian/CIS clinical framework, with distinctive paediatric-neurology emphasis. Licensed indications include perinatal CNS injury, developmental delay, ADHD-adjacent research applications, and post-stroke cognitive recovery. The paediatric-neurology emphasis is broader than any of the other Russian/CIS multi-component neuropeptide preparations.
For research applications outside Russia/CIS, no entry for either compound was found in the electronic medicines compendium (emc) or on the EMA's list of centrally authorised medicines on 17 October 2026. Pinealon offers the defined-molecule methodological advantage; Cortexin offers the substantial Russian clinical-context evidence base and the paediatric-indication licensed-use context that provides distinctive research-tool positioning.